EUVIMEDEUVIMED entdecken
Crossref

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC

Fei Zhou, Xiangjiao Meng iD, Qingqing Ding, Peng Zhang iD, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui iD und 27 weitere

New England Journal of Medicine · 25.10.2026

DOI: 10.1056/nejmoa2611280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 25.10.2026. Verfasst von Fei Zhou und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Sichuan Kelun-Biotech Biopharmaceutical.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, China.
  • Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai.
  • Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Medical Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Xiangjiao Meng, Peng Zhang, Jiuwei Cui

Förderung

  • Sichuan Kelun-Biotech Biopharmaceutical

Zitieren

APA

Zhou, F., Meng, X., Ding, Q., Zhang, P., Liang, W., Guo, S., Yu, Y., Yao, W., Fan, Y., Pu, X., Liu, C., Cui, J., Chen, P., Zhong, H., Wang, Y., Huang, Z., Xu, Z., Dong, X., Yi, T., …, & Zhou, C. (2026). Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2611280

Vancouver

Zhou F, Meng X, Ding Q, Zhang P, Liang W, Guo S, et al. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2611280

BibTeX
@article{Zhou2026,
  author = {Zhou, Fei and Meng, Xiangjiao and Ding, Qingqing and Zhang, Peng and Liang, Wenhua and Guo, Sanxing and Yu, Yan and Yao, Wenxiu and Fan, Yun and Pu, Xingxiang and Liu, Chunling and Cui, Jiuwei and Chen, Peng and Zhong, Hua and Wang, Yongsheng and Huang, Zhangzhou and Xu, Zhi and Dong, Xiaorong and Yi, Tienan and Hu, Ying and Wang, Qiming and Chen, Bolin and Wang, Hui and Sun, Longhua and He, Lang and Zheng, Wei and Wang, Yina and Zhang, Xiaochen and Yao, Yu and Li, Yongsheng and Yang, Zhe and Ye, Feng and Song, Xia and Zhou, Ming and Yin, Li and Qing, Yan and Jin, Xiaoping and Ge, Junyou and Zhou, Caicun},
  title = {Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2611280}
}
Kostenlos starten →